Vivos Inc (RDGL)

[overunder]

Agreed, truly exciting!!

From their press release dated Jan. 09, 2019 titled Vivos Inc 2018 Highlights, Vivos listed 5 strategic objectives.

-Initiate the commercial sales of IsoPet. 1st patient identified. 1st sale coming soon.

-Secure adequate funding to expand IsoPet therapy in key regional centers. $5 million.

-Begin the pre-clinical testing for human therapy. ???FDA always a question mark???

-File for additional patent(s) to enhance our intellectual property protection. PR'ed July 2nd.

-Continue to reduce production costs to make IsoPet more affordable for the average pet owner. Possibly part of the new patents PR'ed July 2nd.

Looks like 4 down and 1 to go for the year.

I like the how they roll up their sleeves and chop away at their to do list. Congrats to Dr. Korenko and all involved! Thank You George Sharp. What an amazing story and a tremendous treatment for beloved pets.


All just my opinion